Oncopeptides enters into additional guarantee commitments, rights issue fully guaranteed

MARKN.

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, HONG KONG, ISRAEL, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO BUY SECURITIES IN ONCOPEPTIDES AB (PUBL). SEE ALSO THE SECTION “IMPORTANT INFORMATION” BELOW IN THIS DOCUMENT.

On 21 August 2025, the Board of Directors of Oncopeptides AB (publ) (“Oncopeptides” or the “Company”) (Nasdaq Stockholm: ONCO) resolved, by virtue of the authorization from the Annual General Meeting on 22 May 2025, to carry out a rights issue of approximately SEK 150 million (the “Rights Issue”). At the time of the announcement, the Rights Issue was covered by subscription undertakings, subscription intentions and guarantee commitments up to approximately 87 percent, corresponding to SEK 130 million. The Company has now received additional guarantee commitments of approximately SEK 20 million (the “New Guarantee Commitments”) which entails that subscription undertakings and guarantee commitments cover 100 percent of the Rights Issue. The New Guarantee Commitments are so-called top guarantees.

For the New Guarantee Commitments, cash compensation is paid of 8 percent of the guaranteed amount, which also corresponds to the guarantee compensation for the guarantee commitments previously entered into. The New Guarantee Commitments secure the SEK 20 million which was not covered by previous undertakings, which results in a fully guaranteed Rights Issue.
 
As communicated in the press release on 21 August 2025, certain board members and senior executives intended to enter into binding subscription undertakings following the publication of the Company’s interim report for the second quarter of 2025 on 21 August 2025. The binding subscription undertakings have been entered into.
 
Neither the New Guarantee Commitments nor the previous guarantee commitments or subscription undertakings are secured by bank guarantee, blocked funds, pledges or similar arrangements.
 
“Since announcing the rights issue, we have received positive feedback from investors including an opportunity to guarantee the remaining SEK 20 million. To ensure the rights issue becomes fully subscribed, the company has therefor decided to enter into these additional guarantee commitments.” says Sofia Heigis, CEO of Oncopeptides. “We are grateful for the positive reactions we have received and remain fully committed to continuing our hard work to deliver strong results.”
 
Disclosure document
Full terms of the Rights Issue and certain information about the Company will be presented in a disclosure document in accordance with Article 1.4 db of the Regulation (EU) 2017/1129 of the European Parliament and of the Council (the “Prospectus Regulation”). The disclosure document, prepared in accordance with Annex IX to the Prospectus Regulation, is expected to be published on or around 28 August 2025.

Datum 2025-08-25, kl 20:40
Källa MFN
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 125 000 sidvisningar och 17 000 unika besökare per månad. Vår discord har 7800 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!